Dukes C期结肠癌术后持续腹腔化疗的临床研究  

Clinical observation of postoperative sustained peritoneal chemotherapy in Dukes C-stage colon cancer

作　　者：马向东[1] 吕孝鹏[1] 宋涛[1] 刘鹏[1] 韩锡林[1] 

机构地区：[1]徐州市中心医院肿瘤外科,221009

出　　处：《中国肿瘤临床与康复》2006年第5期413-415,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨持续腹腔化疗在预防Dukes C期结肠癌术后复发中的价值。方法选择我院1992年6月到2002年6月间行根治术的Dukes C期结肠癌102例,随机分为腹腔化疗组52例和静脉化疗组50例。观察两组患者化疗后不良反应,1,3年生存率和1年无瘤生存率,并进行分析比较。结果腹腔化疗组与静脉化疗组1,3年生存率分别为94.2%、78.8%和92.0%、58.0%,1年生存率差异无显著性(P>0.05),3年生存率差异有显著性(P<0.05),1年无瘤生存率分别为90.4%和74.0%,差异有显著性(P<0.05)。结论Dukes C期结肠癌行根治术后患者辅以持续腹腔化疗能明显降低肿瘤的复发,提高生存率。Objective To explore the value of postoperative sustained peritoneal chemotherapy in prevention of relapse of Dukes C-stage colon cancer. Methods From Jun 1992 to Jun 2002, 102 patients after radical surgery of Dukes C-stage colon cancer were divided into groups at random. One group was treated with intravenous chemotherapy and another with sustained peritoneal chemotherapy. The side effects of chem- otherapy were observed. The 1- and 3- year survival rates and the 1- year tumor-free survival rates were ana- lyzed. Results The 1- and 3- year survival rates of the peritoneal chemotherapy group（94.2% ,78.8% ） were much higher than those of the intravenous chemotherapy group （92.0% ,58.0% ）. The 1- year survival rate had no significant difference（ P 〉 0.05） ,while the 3- year survival rate had significant difference（ P 〈 0.05）. The 1- year tumor-free survival rate of peritoneal chemotherapy group（90.4% ） was much higher than that of the intravenous chemotherapy group （74.0%）, with significant difference （ P 〈 0.05 ）. Conclusion Patients with Dukes C-stage colon cancer were adaptable to sustained peritoneal chemotherapy after radical operation, which reduced peritoneal metastasis rate and hepatic metastasis rate, and increased survival rate.

关 键 词：结直肠肿瘤/化学疗法 

分 类 号：R735.3[医药卫生—肿瘤] R730.53[医药卫生—临床医学]